Biological activity-profile modeling identifies SARS-CoV-2 antiviral leads
NCATS researchers used biological activity-based modeling (BABM) to infer antiviral activity from compounds’ profiles across multiple assays. Of 311 model-predicted SARS-CoV-2 candidates tested in a live-virus cell-culture assay, 99 were confirmed active (32% hit rate); follow-up assays implicated viral-entry inhibition and/or autophagy modulation among confirmed compounds.
Technology: Biological activity-based modeling (BABM) models trained on multi-assay compound-activity profiles
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: NCATS researchers used biological activity-based modeling (BABM) to infer antiviral activity from compounds’ profiles across multiple assays.
- Still unknown: Evidence is from cell-culture live-virus and mechanistic assays, not clinical treatment. 99/311 were active in the primary assay; further potency/secondary confirmations were available for subsets. Most confirmed compounds were reported to inhibit entry and/or modulate autophagy; these data do not establish safe or effective human therapy.
- AI role: BABM used prior activity signatures across assay panels to predict compounds with potential SARS-CoV-2 activity, including compounds outside conventional similar-structure hit finding. Researchers tested 311 model-predicted compounds in live-virus assays and conducted secondary/mechanistic assays on confirmed actives.
Evidence sources: https://www.nature.com/articles/s41587-021-00839-1
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 10% of works of the same type, year and subfield (OpenAlex work metrics, 54 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.